Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023
Central Nervous System
IGC starts clinical trial of drug candidate to treat agitation in dementia
The objective of the trial is to establish IGC-AD1’s efficacy in helping dementia patients reduce neuropsychiatric symptoms.
A third of all schizophrenia cases go undiagnosed
Argenica announces first subject dosing in third cohort of ARG-007 trial
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Positive data for Luye Pharma’s LY03010 in schizophrenia, but faces a crowded marketop
Telix doses first subject in Phase II glioblastoma therapy trial
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
